Drugs / LONDAMOCITINIB
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT06732882 | Feb → May 2025 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06519968 | Jul → Dec 2024 | — | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT06157255 | Feb → May 2024 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT04769869 | Jul 2022 → Jan 2023 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06435273 | Aug 2024 → Oct 2025 | asthma | AstraZeneca | Completed | No outcome recorded |
| Phase 2 | NCT06020014 | Nov 2023 → Oct 2025 | asthma | AstraZeneca | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2024-05-01 | AstraZeneca | Results AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio astrazeneca.com ↗
Findings from a preclinical study of AZD4604, an inhaled, small molecule selective Janus Kinase 1 (JAK1) inhibitor in development for the treatment of moderate-to-severe asthma. |
All press releases naming this drug 1 release
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LONDAMOCITINIB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4447181 ↗ |
| Known as | AZD4604 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06157255 ↗ |
| Action | Inhibit | “Janus kinase 1 (JAK1) inhibitor” NCT06435273 ↗ |
| Modality | Small molecule | — CHEMBL4447181 ↗ |
| Route | Inhaled | “inhaled AZD4604” NCT04769869 ↗ |
| Target | JAK1 | “Janus kinase 1 (JAK1) inhibitor” NCT06435273 ↗ |